Bio-Rad Laboratories Reports Q4 and Full-Year 2025 Financial Results: Revenue Growth Amid Segment Challenges

on

Q4 2025 net sales:
$693.2 million, up 3.9% YoY (1.7% currency neutral), driven by Clinical Diagnostics segment growth of 8.4% (5.6% currency neutral)123

Life Science segment Q4 sales:
$267.9 million, down 2.6% YoY (4.0% currency neutral) due to constrained academic research and biotech funding1

Full-year 2025 net sales:
$2,583.2 million, up 0.7% YoY (flat currency neutral); Clinical Diagnostics up 0.8%, Life Science down 1.3% currency neutral14

Q4 GAAP net income:
$720.0 million ($26.65 EPS), swing from $715.8 million loss in 2024, driven by $1,029.5 million gain from equity securities and loan receivable34

Full-year 2025 GAAP net income:
$759.9 million ($27.85 EPS) vs. $1,844.2 million loss in 20243

Q4 GAAP operating loss: ~$119 million (vs. $58 million income prior year) due to $173 million impairment charges; non-GAAP operating margin:
12.0%4

Cash and equivalents end of year:
$532.2 million, up from $489.8 million1

Future plans:
New product launches in 2026 including IVD QX600 and ddPCR assays2

Sources:

1. https://www.businesswire.com/news/home/20260212976030/en/Bio-Rad-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results

2. https://www.gurufocus.com/news/8613033/biorad-bio-reports-q4-revenue-growth-and-strategic-initiatives

3. https://www.nasdaq.com/articles/bio-rad-laboratories-swings-q4-profit

4. https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-q4-earnings-call-highlights-2026-02-12/